What question did this study set out to answer?

February 11, 2004BMJOpen Access

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)

View Full Paper

Ask AI

Bookmark

Why the study?

Does low dose (1.25 mg) ramipril once daily improve cardiovascular and renal outcomes in patients with type 2 diabetes and albuminuria?

Population

Patients with type 2 diabetes and raised excretion of urinary albumin (albuminuria)

Comparison

Low dose (1.25 mg) ramipril once daily vs Placebo

Design

RCT, randomised, double blind

Authors

MMMichel MarrePreventive Cardiology MLMichel LièvreStructural Heart Disease GCGilles ChâtellierUniversité Claude Bernard Lyon 1

Discussion

Member takes

Implication

Low-dose ramipril lacks cardiovascular and renal benefits in type 2 diabetes with albuminuria; confirms dose-dependent efficacy of higher doses in prior RCTs.

Key Points

To evaluate the impact of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised urinary albumin.
Randomized, double-blind, placebo-controlled trial
Participants received either 1.25 mg of ramipril or placebo
Assessed effects on cardiovascular and renal outcomes over the study duration.
No significant effect on cardiovascular and renal outcomes observed with low dose ramipril
Slight decrease in blood pressure noted
Slight decrease in urinary albumin levels but no clinical significance.

Structured PICO

Does low dose (1.25 mg) ramipril once daily improve cardiovascular and renal outcomes in patients with type 2 diabetes and albuminuria?

Population

Patients with type 2 diabetes and raised excretion of urinary albumin (albuminuria)

Intervention

Low dose (1.25 mg) ramipril once daily

Comparator

Placebo

Outcome

Cardiovascular and renal outcomeshard clinical

Low-dose ramipril (1.25 mg/day) does not provide the cardiovascular and renal benefits observed with higher doses (10 mg/day) in patients with type 2 diabetes and albuminuria.

Cite This Study

Marre et al. (2004) studied this question.

synapsesocial.com/papers/69d570e575589c71d767dfdf https://doi.org/10.1136/bmj.37970.629537.0d

View Full Paper

Ask AI

Bookmark

Implication

Low-dose ramipril lacks cardiovascular and renal benefits in type 2 diabetes with albuminuria; confirms dose-dependent efficacy of higher doses in prior RCTs.

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider